

THERMO FISHER SCIENTIFIC INC.

Form 8-K

November 10, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report  
(Date of earliest event reported):  
November 4, 2009**

**THERMO FISHER SCIENTIFIC INC.**

(Exact name of Registrant as specified in its Charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

1-8002  
(Commission File Number)

04-2209186  
(I.R.S. Employer  
Identification Number)

81 Wyman Street  
Waltham, Massachusetts  
(Address of principal executive offices)

02451  
(Zip Code)

(781) 622-1000  
(Registrant's telephone  
number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

Thermo Fisher Scientific Inc. (the Company) received notice on November 4, 2009 that Inverness Medical Innovations Inc. (Inverness), has elected to terminate its contract with the Company covering Biosite products, effective July 1, 2010. Under this contract, the Company's healthcare market business purchases Biosite products for resale to third-party customers. The Company believes that Inverness' decision to terminate the contract and sell direct to customers was made in response to the Company's recent strategic decision to expand its product offerings in order to provide its customers with a broader menu of diagnostic solutions. The Company expects approximately \$200 million in revenue from the sale of Biosite products in 2009. As a consequence of the termination, the Company expects that sales of Biosite products in 2010 will be less than half of the 2009 level and will be minimal in 2011 and beyond. The Company has signed an agreement with another supplier of diagnostic products and expects to sell approximately \$40 million of these and other products from the new supplier in 2010, offsetting a portion of the anticipated drop in revenue from the Biosite products.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on this 10th day of November, 2009.

THERMO FISHER SCIENTIFIC INC.

By: /s/ Seth H. Hoogasian  
Seth H. Hoogasian  
Senior Vice President, General Counsel  
and Secretary